Sagility Achieves Major Sustainability Milestone with SBTi Validation of GHG Emissions Targets
BENGALURU, India, June 3, 2025 /PRNewswire/ -- Sagility India Limited (NSE: SAGILITY)…
Libtayo (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or…
Global Experts Warn WHO’s Anti-Harm Reduction Stance Undermines World No Tobacco Day
WASHINGTON, May 29, 2025 /PRNewswire/ -- A panel of global tobacco harm…
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated…
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements…
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and…
Bit Origin Ltd Announces Court Hearing on June 5, 2025, for Share Capital Reduction
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Bit Origin Ltd (NASDAQ:…
Infineon gains approval of Science Based Targets initiative for ambitious CO2 emission reduction targets
Scope 1 and 2 targets meet highest SBTi standard for near-term reduction goalsInfineon…
TARIFFS BITE: NORTH AMERICAN AND ASIAN MANUFACTURERS RETRENCH IN APRIL, WITH GLOBAL MATERIAL PURCHASES DOWN AT ACCELERATED PACE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
The steep fall in global manufacturers' purchases signals a likely production slowdown…
UPL LTD – Q4 and FULL YEAR FY25 RESULTS UPDATE
Strong Financial Performance for FY25; 8% Revenue Growth, 175% Growth in Net…